Literature DB >> 3883922

Immunodiagnosis of human malignancy.

H F Seigler.   

Abstract

Definition of normal cell membrane antigens using immunologic techniques has permitted investigators to distinguish normal cells from malignant cells. Malignant cells express fetal antigens in concentrations different from normal mature cells. Mutant cells express differentiation as well as those antigens reflecting the altered cell genome. Normal cells can be transformed into malignant cells using either chemical agents or viruses. As these agents are incorporated into the genome, surface antigens are expressed that differ from normal cell isoantigens. These antigenic determinants can serve as tumor-associated or perhaps tumor-specific markers. Immunochemical methods now exist that permit isolation and purification of these antigens. Monoclonal antibodies have been generated that react with single epitopes associated with these antigens. Very sensitive and highly specific radioimmunoassays and enzyme immunosorbent assays can detect microgram quantities of these antigens in body fluids and as such permit serodiagnostic evaluation. Monoclonal antibodies can also be used for radioautography, immunofluorescent, and immunoperoxidase staining for diagnostic purposes of both cytologic and fixed tissue sections. The binding affinity and specificity of these monoclonal antibody reagents has successfully been used for in vivo tumor localization. Isotopically labeled monoclonal antibodies bind preferentially to tumor cells in the host and are useful for specific radionuclide scintigraphy. These recently developed immunodiagnostic techniques not only add specificity in terms of diagnostic accuracy but are useful for early detection of recurrent disease and in vivo localization of tumor deposits. Therapeutic implications are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3883922      PMCID: PMC1250727          DOI: 10.1097/00000658-198504000-00003

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  14 in total

Review 1.  Monoclonal and polyclonal antibodies against neural antigens: diagnostic applications for studies of central and peripheral nervous system tumors.

Authors:  J Q Trojanowski; V M Lee
Journal:  Hum Pathol       Date:  1983-04       Impact factor: 3.466

2.  Structural characterization of the 'melanoma-specific' antigen detected by monoclonal antibody 691I5Nu-4-B.

Authors:  K F Mitchell; J P Fuhrer; Z Steplewski; H Koprowski
Journal:  Mol Immunol       Date:  1981-03       Impact factor: 4.407

3.  Monoclonal antibodies to human malignant melanoma.

Authors:  R A Reisfeld
Journal:  Nature       Date:  1982-07-22       Impact factor: 49.962

4.  Use of panels of monoclonal antibodies in the differential diagnosis of neuroblastoma and lymphoblastic disorders.

Authors:  J T Kemshead; A Goldman; J Fritschy; J S Malpas; J Pritchard
Journal:  Lancet       Date:  1983-01-01       Impact factor: 79.321

5.  Monoclonal antibody detection of a circulating tumor-associated antigen. II. A longitudinal evaluation of patients with colorectal cancer.

Authors:  H F Sears; M Herlyn; B Del Villano; Z Steplewski; H Koprowski
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

6.  Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues.

Authors:  J P Brown; R G Woodbury; C E Hart; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

7.  Oncogenes of RNA tumor viruses as determinants of cancer.

Authors:  R J Huebner; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1969-11       Impact factor: 11.205

8.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

9.  Monoclonal antibody to ganglioside GQ discriminates between haemopoietic cells and infiltrating neuroblastoma tumour cells in bone marrow.

Authors:  J T Kemshead; F Walsh; J Pritchard; M Greaves
Journal:  Int J Cancer       Date:  1981       Impact factor: 7.396

10.  In vivo tumor localization using tumor-specific monkey xenoantibody, alloantibody, and murine monoclonal xenoantibody.

Authors:  G M Stuhlmiller; D C Sullivan; C E Vervaert; B P Croker; C C Harris; H F Seigler
Journal:  Ann Surg       Date:  1981-11       Impact factor: 12.969

View more
  1 in total

1.  Computational and in vitro Investigation of miRNA-Gene Regulations in Retinoblastoma Pathogenesis: miRNA Mimics Strategy.

Authors:  Nalini Venkatesan; Perinkulam Ravi Deepa; Vikas Khetan; Subramanian Krishnakumar
Journal:  Bioinform Biol Insights       Date:  2015-05-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.